Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
L.E.A.F. Holdings Group LLC is managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 6 actions are distributed among 5 distinct examiners, indicating a slight concentration in the workload. ISAAC SHOMER is the busiest examiner for the portfolio, holding 2 pending office actions. This means that while most examiners handle one case, one examiner is responsible for a larger share of the pending matters.
The 6 pending office actions are situated within 3 distinct art units, which suggests a relatively focused technical scope despite the involvement of 5 examiners. With 6 pending actions and 3 art units, the company may benefit from some consistency in technical review across its applications. However, the need to manage 5 different examiners, including ISAAC SHOMER who holds 2 pending actions, still requires a varied prosecution strategy.
Practitioners should prioritize their approach for the 2 pending office actions assigned to ISAAC SHOMER, as this represents the only point of examiner concentration. The 3 distinct art units provide a framework for the 6 pending matters, but the diversity of 5 examiners still demands a case-by-case analysis. This profile indicates a specialized biotechnology portfolio that requires balancing a primary examiner relationship against several individual ones.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 2 | 63.2% | +30.4% |
| CABRAL, ROBERT S | 1 | 62.6% | +32.5% |
| KAMM, JUDITH MARIE | 1 | 43.5% | +56.6% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018205 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | KAMM, JUDITH MARIE | 26d |
| 19018165 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | SHOMER, ISAAC | — |
| 18968387 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | SHOMER, ISAAC | — |
| 17917910 | METHODS OF SYNTHESIZING CAROTENOIDS | JARRELL, NOBLE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018205 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | KAMM, JUDITH MARIE | 26d |
| 19018165 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | SHOMER, ISAAC | — |
| 18968387 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | SHOMER, ISAAC | — |
| 18755082 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | CABRAL, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19018165 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | SHOMER, ISAAC | — | §102§112Other | Non-Final OA | — | Pending | Jan 13, 2025 |
| 18968387 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | SHOMER, ISAAC | — | §102§112Other | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18755082 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | CABRAL, ROBERT S | 1614 | DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18018205 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | KAMM, JUDITH MARIE | 1611 | §103§112Other | Final Rejection | 26d | Pending | Jan 26, 2023 |
| 17917910 | METHODS OF SYNTHESIZING CAROTENOIDS | JARRELL, NOBLE E | — | §102§112 | Non-Final OA | — | Pending | Oct 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial